Efficacy of icotinib in the treatment of advanced lung cancer patients and its effect on the level of T cell subsets
Objective To investigate the efficacy of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibi-tor(TKI)targeting drug icotinib in the treatment of advanced lung cancer patients and its effect on the level of T cell sub-sets.Method A total of 86 patients with advanced lung cancer were divided into control group(n=45)and observation group(n=41)according to different treatment regimens.Control group received conventional chemotherapy,observation group received conventional chemotherapy combined with icotinib treatment.The clinical efficacy,T cell subsets(CD3+,CD4+,CD8+)levels,pulmonary function indicators[forced vital capacity(FVC),maximal mid-expiratory flow(MMEF),forced expiratory volume in one second(FEV1)]and the incidence of adverse reactions were compared between the two groups.Result The clinical total control rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3+and CD4+in observation group were higher than those before treatment and control group,and the levels of CD8+were lower than those before treatment and control group,the differences were statistically significant(P<0.05).Before and after treatment,there were no significant differ-ences in FEV1,FVC and MMEF between the two groups(P>0.05).There was no significant difference in the total inci-dence of adverse reactions between the two groups(P>0.05).Conclusion EGFR-TKI targeting drug icotinib has good clinical efficacy in the treatment of advanced lung cancer patients,and can improve the immune function of the body,with good safety.
advanced lung cancerepidermal growth factor receptortyrosine kinase inhibitoricotinibimmune functionlung function
NETL
NSTL
万方数据
